
Oral TOFA boosts fat burning and may preserve muscle in weight loss
Researchers at UC Berkeley identified TOFA, an oral compound that reduced body weight in obese mice by about 18% by increasing energy expenditure rather than suppressing appetite, and it preserved lean mass; when paired with GLP-1 drugs such as semaglutide or tirzepatide, it produced greater weight loss and improved metabolic markers; TOFA also showed liver benefits in mouse models of fatty liver disease, without raising triglycerides. The effects in humans are unknown, the study involved only male mice, and questions remain about dosing, safety, and long-term risks before any human use.













